Mobia Medical, Inc. - Common Stock (MOBI)

New guideline recognition is fueling this stroke device maker's commercial expansion.

Mobia Medical (NASDAQ:MOBI) raised its full-year revenue forecast after third-quarter sales rose 73%, driven by broader adoption of its Vivistim therapy at new and existing programs. The company reported revenue of $15.6 million for the quarter ended Sept. 30, 2026, up from $9 million a year earlie

Revenue doubled as Vivistim unit sales and active territories expanded.

Mobia Medical (NASDAQ:MOBI) reported second-quarter revenue of $13.5 million, up 102% from $6.7 million a year earlier, as adoption of its Vivistim paired vagus nerve stimulation therapy expanded across new and existing stroke-care programs. The company, which completed its initial public offering